AC Immune receives a "Buy" rating, driven by positive phase 2 VacSYn trial results for ACI-7104.056 in early Parkinson's ...

Utah (12.6) and Kansas (11.5) lead the nation in Parkinson's mortality, with Ohio and neighboring states also showing ...

Researchers are developing a greater understanding of Parkinson’s disease, the fastest growing neurodegenerative disease ...

People with restless leg syndrome may also have a higher risk for Parkinson's disease, a study from the Republic of Korea has ...

The treatment uses a modified, harmless virus to deliver healthy genes to a patient’s cells to treat genetic diseases. Read ...

Lindberg had Parkinson’s disease, the neurologist said, with all the classic symptoms. PD—as the scientists she would meet ...

The brain-chemical surge that comes with running may bolster coordination and speed in the old and young alike, a new study ...

Most people wait for a visible shake to worry about neurological health, but the disease often starts much earlier with ...

Investing.com -- AC Immune (NASDAQ:ACIU) stock rose 25% after the company reported positive interim Phase 2 data for its Parkinson’s disease treatment, suggesting the therapy may slow disease ...

AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s DiseaseResults show, for the ...

Parkinson's disease is a neurogenerative disorder that affects predominately the dopamine-producing (dopaminergic) neurons in the brain. People suffering from it face problems in motor movement, ...

A study conducted at São Paulo State University indicates that the non-invasive technique provides lasting benefits by reducing the risk of falls. The study involved 22 volunteers with Parkinson's. di ...